Stock	New 52-Week Low	Previous 52-Week Low	Previous Date

Alzinova	0.75	0.76	2026-01-09
Betsson B	132.90	133.60	2026-01-08
Hacksaw	58.25	59.08	2025-12-22
Spectracure	0.11	0.12	2026-01-12

Source: FactSet

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
ALZINOVA AB	0.7040SEK	-0.98%	-3.43%	8.23M
HACKSAW AB	58.10SEK	+2.31%	+5.41%	1.82B
BETSSON B	92.20SEK	+2.39%	+0.82%	1.37B
SPECTRACURE AB	0.0992SEK	-3.50%	-3.50%	4.68M

Latest news about Alzinova AB

02-06	48 Stocks Hit New 52-Week Lows on the Stockholm Stock Exchange So Far Today	FW
02-03	Calendar Tuesday, February 3	FW
01-19	Alzinova Engages in In-Depth Partnership Discussions at Healthcare Conference	FW
01-19	16 Stocks Reach New 52-Week Lows Today on the Stockholm Stock Exchange	FW
01-16	Five Stocks Hit New 52-Week Lows on the Stockholm Stock Exchange Today	FW
01-15	Seven Stocks Reach New 52-Week Lows on the Stockholm Stock Exchange Today	FW
01-13	Four Stocks Hit New 52-Week Lows on the Stockholm Stock Exchange Today	FW
12-29	Alzinova's CFO Erik Kullgren Makes Minor Share Purchase	FW
12-29	Nine Stocks Hit New 52-Week Lows Today on the Stockholm Stock Exchange	FW
12-23	Eight Stocks Hit New 52-Week Lows on the Stockholm Stock Exchange Today	FW
12-23	Intrum Takes Billion-Krona Write-Down Amid Mixed Stockholm Stock Exchange; OMXS30 Index Rises 0.1 Percent	FW
12-22	Alzinova raises proceeds of about SEK 50 mln from rights issue	RE
12-22	Alzinova Seeks to Raise Approximately SEK 50 Million Through Rights Issue of Units	FW
12-04	Alzinova enters MoU for commercial partnership in Saudi Arabia	RE
12-04	Alzinova signs letter of intent for partnership in Saudi Arabia	FW

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

02-26 - Q4 2025 Earnings Release

More about the company